Annexon, Inc. — Q1 2024 Form 10-Q Summary
Business context and reporting period
Annexon is a clinical-stage biopharmaceutical company developing complement-pathway medicines targeting inflammatory diseases. The filing covers the unaudited three months ended March 31, 2024, compared with the three months ended March 31, 2023. The company has no approved products and has generated no product revenue.
- Priority programs: ANX005 for Guillain-Barré syndrome, ANX007 for geographic atrophy, and oral ANX1502 for autoimmune indications.
- ANX005 Phase 3 GBS enrollment was completed with 241 patients; data were anticipated in Q2 2024. Real-world evidence comparability data using IGOS were anticipated in the first half of 2025.
- Annexon planned to initiate the Phase 3 ARCHER II trial for ANX007 in mid-2024 and the ARROW head-to-head trial against SYFOVRE in late 2024.
- ANX1502 proof-of-concept testing in cold agglutinin disease was planned for the first half of 2024, with data expected in the second half of 2024.
Financial condition and results
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Product revenue | $0 | $0 | No change |
| Research and development expense | $21.0 million | $32.3 million | Down 35% |
| General and administrative expense | $7.6 million | $8.9 million | Down 14% |
| Total operating expenses | $28.6 million | $41.2 million | Down 31% |
| Interest and other income, net | $3.4 million | $2.6 million | Up 32% |
| Net loss | $25.2 million | $38.7 million | Loss decreased 35% |
| Basic and diluted net loss per share | $0.21 | $0.52 | Improved |
| Net cash used in operating activities | $28.3 million | $33.0 million | Improved by $4.7 million |
Because the company has no revenue, gross margin and operating margin are not meaningful. The operating loss was $28.6 million in Q1 2024. Stock-based compensation was $4.7 million, compared with $4.6 million in the prior-year quarter.
- Cash and investments: Cash and cash equivalents were $151.9 million and short-term investments were $113.0 million at March 31, 2024, totaling $264.9 million. Including restricted cash, cash, cash equivalents and restricted cash totaled $153.0 million.
- Liquidity: Management stated that existing cash and investments were expected to fund operating expenses and capital requirements into mid-2026, subject to assumptions and potential changes in the operating plan. The notes separately state that resources would fund requirements for at least twelve months from issuance of the financial statements.
- Debt and leases: The filing does not report debt borrowings. Operating lease liabilities totaled $30.8 million, including $2.3 million current and $28.5 million non-current.
- Equity: Stockholders’ equity was $262.4 million at March 31, 2024, versus $250.6 million at December 31, 2023. The accumulated deficit was $597.7 million.
- Shares and potential dilution: 90.5 million shares were outstanding at March 31, 2024; 92.4 million were outstanding as of May 8, 2024. As of March 31, 2024, 35.2 million shares were issuable upon exercise of pre-funded warrants and 8.4 million upon exercise of common warrants, in addition to outstanding equity awards.
Material changes versus the prior comparable period
- R&D expense declined $11.4 million, primarily due to lower contract manufacturing costs for ANX005 clinical supply, completion of the Phase 2 ARCHER trial, and lower personnel costs. These reductions were partly offset by higher facilities and depreciation costs following expiration of the sublease.
- G&A expense declined $1.3 million, primarily from lower consulting and professional services costs and reduced headcount-related costs.
- Interest and other income increased $0.8 million due mainly to favorable interest rates.
- Operating cash burn decreased from $33.0 million to $28.3 million, while investing cash flow shifted from $19.5 million of inflow to $77.3 million of outflow as the company purchased additional available-for-sale securities.
- Financing cash inflow increased to $32.4 million, including $32.2 million of net proceeds from the 2021 ATM program, compared with $17.6 million in Q1 2023.
- During Q1 2024, Annexon sold 6.6 million shares under the 2021 ATM program for approximately $32.2 million of net proceeds. Approximately $48.9 million remained available under that program at quarter-end. A new $100.0 million ATM program was established in March 2024, with no sales completed under it by March 31.
Outlook, risks, contingencies and unusual items
- Annexon expects continuing losses and negative operating cash flows for at least the next several years and will require substantial additional financing to achieve its development objectives.
- Additional financing may be obtained through equity, debt, collaborations or other sources. Equity financing would dilute existing holders; debt could impose covenants and repayment obligations.
- The company stated that additional capital will be needed to complete the planned ANX007 ARROW trial, even though current resources are expected to fund operations into mid-2026.
- Key execution risks include clinical-trial delays or failures, patient enrollment, foreign-trial data acceptance, regulatory requirements for one or more pivotal trials, safety findings, third-party manufacturing and supply, intellectual-property challenges, reimbursement, competition and the ability to raise capital.
- ANX007 faces competition from two approved geographic-atrophy therapies and regulatory uncertainty regarding whether ARCHER II and ARROW will provide sufficient evidence for approval.
- The company relies on third parties for clinical development and manufacturing and has no internal commercial manufacturing or sales infrastructure.
- The filing reports no material legal proceedings, no defaults upon senior securities and no unregistered sales of equity securities during the quarter.
- A vendor experienced a cybersecurity attack in 2024 that briefly interrupted access to a third-party system; the company stated that it was monitoring the incident and had implemented mitigating procedures.
- Disclosure controls and procedures were assessed as effective, with no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Verify Q2 2024 ANX005 Phase 3 GBS data, subsequent regulatory plans and the status of the IGOS comparability effort.
- Verify initiation, enrollment, endpoints, comparator design and funding requirements for ANX007 ARCHER II and ARROW.
- Reconcile the stated mid-2026 cash runway with quarterly operating cash burn, planned clinical spending and the need for additional capital.
- Track ATM activity, remaining capacity, pre-funded warrant exercises and the resulting fully diluted share count.
- Assess whether reduced Q1 R&D spending reflects sustainable prioritization or timing-related fluctuations, particularly for manufacturing and clinical costs.
- Monitor regulatory acceptance of foreign clinical data, manufacturing readiness, safety findings and competitive developments in geographic atrophy.